Patients with Better Vision to be Enrolled in ACT’s Clinical Trials for Macular Degeneration

  Patients with Better Vision to be Enrolled in ACT’s Clinical Trials for
  Macular Degeneration

  Patients with 20/100 Vision Will Now be Eligible for Enrollment, Expanding
           Patient Base and Potentially Accelerating Pace of Trials

Business Wire

MARLBOROUGH, Mass. -- January 22, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader
in the field of regenerative medicine, announced today that it is amending the
patient treatment protocol for the remainder of the Company’s Phase I clinical
trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular
degeneration (dry AMD) currently being conducted in the U.S. and will also
submit an amendment in Europe for the SMD trial being conducted there.
Patients with better vision, a visual acuity of 20/100, will be eligible for
enrollment in the remainder of the trials. By treating patients earlier in the
course of the disease, the Company believes that the amended patient protocol
will have a more significant impact on photoreceptor rescue and visual
function. In previous protocols, only SMD patients with a visual acuity no
better than hand movement in the treated eyes and dry AMD patients with a
visual acuity of 20/400 were eligible.

“Having recently reached the halfway point in our three clinical trials for
macular degeneration, now is an opportune time to pursue modifications which
could help accelerate the pace of all three trials,” said Gary Rabin, chairman
and CEO. “The advanced age of many of our enrolled patients has tended to
limit the pace at which we are able to enroll and treat them, since other,
unrelated health complications tend to come up more frequently in the elderly.
Patients with better vision tend to be younger on average.”

The Company plans to institute the amended patient protocols upon receipt of
Institutional Review Board (IRB) approval from each of the clinical sites, for
the second half of all the clinical trials.

“We are pleased to be able to expand patient enrollment in all three of our
ongoing clinical trials,” said Robert Lanza, M.D., ACT’s chief scientific
officer. “Not only does it have the potential to accelerate the road to the
completion of Phase I, but having a more diverse patient population could also
provide additional clinical insights.”

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT
Bill Douglass, 646-450-3615
Corporate Communications,
or:
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.